{"name":"Fundação Bahiana de Infectologia","slug":"funda-o-bahiana-de-infectologia","ticker":"","exchange":"","domain":"","description":"Fundação Bahiana de Infectologia is a research-focused organization dedicated to the study and treatment of infectious diseases, particularly HIV/AIDS. The foundation is involved in clinical trials and the development of antiretroviral therapies, contributing significantly to the advancement of healthcare in Brazil.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dolutegravir plus lamivudine in a FDC","genericName":"Dolutegravir plus lamivudine in a FDC","slug":"dolutegravir-plus-lamivudine-in-a-fdc","indication":"HIV-1 infection in treatment-naïve or treatment-experienced adults","status":"phase_3"}]}],"pipeline":[{"name":"Dolutegravir plus lamivudine in a FDC","genericName":"Dolutegravir plus lamivudine in a FDC","slug":"dolutegravir-plus-lamivudine-in-a-fdc","phase":"phase_3","mechanism":"Dolutegravir inhibits HIV integrase to prevent viral DNA integration into the host genome, while lamivudine inhibits reverse transcriptase to block HIV replication.","indications":["HIV-1 infection in treatment-naïve or treatment-experienced adults","HIV-1 infection in adolescents and children (age-appropriate formulations)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}